HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Diamandis, E. P. Related Collections Molecular Diagnostics and Genetics Automation and Analytical Techniques

Sequencing with Microarray Technology—A Powerful New Tool For Molecular Diagnostics

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario M5G 1X5, Canada, and, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, Fax 416-586-8628, E-mail ediamandis@mtsinai.on.ca

Nucleic acid sequencing is a fundamental technique that was recognized with the 1980 Nobel Prize in Chemistry. The method allows delineation of DNA sequences with extraordinary accuracy and, since its introduction in the 1970s, has undergone many important modifications and improvements. Among these are the achievement of long reads (up to 1000 bp per analysis), better accuracy (related to the discovery of highly versatile and thermostable sequencing enzymes), improved sensitivity with thermocycling protocols (linear amplifications), full automation, higher speed (related to the introduction of thin gels), and substitution of radioactivity with fluorescent and other probes. All of these improvements have allowed scientists to attempt something that was unthinkable 15–20 years ago, i.e., delineation of the complete sequence of the human genome (3 x 10⁹ bp) and genomes of other organisms. We have already witnessed, over the last few years, the release of the complete sequence of simple organisms as well as of more complex ones, the latest being the Drosophila genome (1). We are now very close to the completion of the entire Human Genome Project (2). These achievements represent a triumph of the DNA sequencing methodology.

Now that we (almost) know the complete DNA sequences of these organisms and humans, the question arises. How are we to use this information? The next step will be the complete annotation of the human genome, which will include classification of the raw DNA sequence into well-defined gene structures. We will then need to predict and experimentally verify the encoded proteins and their possible biological functions (physiology). Once this is done, we can begin to ask questions about how genomic variation in certain genes (polymorphisms, mutations) can cause or predispose to specific human diseases (pathophysiology). We already have many examples of subtle genetic changes that can cause very . . . [Full Text of this Article]

References

The following articles in journals at HighWire Press have cited this article:

				J Peltonen, J A Welsh, and K H Vahakangas Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? Human and Experimental Toxicology, January 1, 2007; 26(1): 9 - 18. [Abstract] [PDF]

				Y. Kohara, H. Noda, K. Okano, and H. Kambara DNA probes on beads arrayed in a capillary, 'Bead-array', exhibited high hybridization performance Nucleic Acids Res., August 15, 2002; 30(16): e87 - e87. [Abstract] [Full Text] [PDF]

				D J Bowen Haemophilia A and haemophilia B: molecular insights Mol. Pathol., April 1, 2002; 55(2): 127 - 144. [Abstract] [Full Text] [PDF]

				D J Bowen Haemophilia A and haemophilia B: molecular insights Mol. Pathol., February 1, 2002; 55(1): 1 - 18. [Abstract] [Full Text] [PDF]

				T. Norberg, S. Klaar, L. Lindqvist, T. Lindahl, J. Ahlgren, and J. Bergh Enzymatic Mutation Detection Method Evaluated for Detection of p53 Mutations in cDNA from Breast Cancers Clin. Chem., May 1, 2001; 47(5): 821 - 828. [Abstract] [Full Text] [PDF]